CLIC-INNOVATION
27.8.2024 13:08:28 CEST | Business Wire | Press release
Rare earth elements and rare magnets play a crucial role in advancing the green energy transition and achieving the goals of the European Green Deal. While the EU currently relies heavily on imports from a few countries— with approximately 90% of REEs* coming from outside the EU—this presents an opportunity to develop European expertise and forge strategic partnerships in rare earth metals processing. Strengthening these capabilities within Europe is key to reaching our ambitious targets. Additionally, while challenges remain in REEs recycling, with current rates being less than 5% and some extraction processes needing sustainability improvements, these challenges also present a significant potential for innovation and growth. As demand for REEs increases, driven by their use in electric vehicles, wind turbine motors, and electrolysers for clean hydrogen, there is a tremendous opportunity to enhance recycling efforts and establish more sustainable extraction processes within the EU.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827785891/en/
CLIC Innovation: REMHub Project Develops a Digital Innovation Hub for Rare Earth Elements and Rare Magnets (Copyright (c) 2024 Phawat/Shutterstock)
Project targets and development areas
REMHub will develop, test and pilot novel technologies for the exploration and primary production of rare earth elements and for recovering them from side streams to enhance supply security of REEs and rare magnets in the EU. In addition, the project will develop Re-X (Recycle, Reuse, refurbishment and repurposing) technologies for rare earths and valuable metals from end-of-life products as well as electric machine design for easier permanent magnet recycling. The project will also identify and engage relevant stakeholders to develop REE value chains in the EU. The innovation hub will ensure that the novel technologies developed in the project will be commercialized and offered as services via digital platform in the future.
The project’s multi-stakeholder communication and dissemination efforts are designed to actively involve and engage the public and various stakeholders, fostering trust and raising awareness about the importance of REEs. These activities also aim to build essential capacities within the EU. The hub focuses on transformative material sourcing for REEs and REE magnets, including innovations in traceability, digital twinning, and digital passports. Our project partners span the entire REE value chain, from mineral exploration and processing to metal production, magnet manufacturing, and recycling.
The project is committed to a safe and sustainable by design (SSbD) framework, embracing a Re-X approach that prioritizes recycling, reuse, refurbishment, and repurposing, while integrating features for easy dismantling and circularity. REMHub is set to significantly enhance the security of REE supply in the EU. With the support of our digital innovation hub, it will accelerate the development of technologies and services, enabling faster and easier market entry. By the conclusion of the project, future organizations will find it much easier to access sustainably developed REE expert services within the EU.
Project in a nutshell
The project will commence at the beginning of October and last for four years. The project consortium consists of 24 partners from six countries: Finland, Estonia, Spain, Ireland, Slovenia, and Italy. The project preparation and consortium coordination were led by the Finnish organization CLIC Innovation, which also serves as the project coordinator. The estimated total volume of the project is 18 million euros, of which 16 million euros is EU funding. The EU Horizon "resilient value chains" funding instrument supports European sustainable development value chain projects with financing from the European Commission.
* source: https://scrreen.eu/wp-content/uploads/2023/08/SCRREEN2_factsheets_REE-EUROSTAT.pdf
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827785891/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
